A Phase II Study of Cyclophosphamide to Prevent Rejection after a Mismatched Unrelated Bone Marrow Transplant in Patients with Blood Cancers


Full Title

15MUDD: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies


In this study, researchers are evaluating the use of the anticancer drug cyclophosphamide given after a human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplant in patients with blood cancers to see if it can reduce the risk of transplant rejection and graft-versus-host disease. They will also assess recipients’ survival, rate of cancer recurrence, and post-transplant complications. Patients will also receive two other anti-rejection drugs after transplantation: sirolimus and mycophenolate mofetil.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have acute leukemia, lymphoma, myelodysplastic syndromes, or chronic lymphocytic leukemia that will be treated with mismatched unrelated bone marrow transplantation.
  • Patients who have had a prior allogeneic (donated) bone marrow transplant may not participate.
  • This study is for patients ages 18 to 70.
p>For more information about this study and to inquire about eligibility, please contact Dr. Brian Shaffer at 212-639-2212.